• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 4:43:08 PM ET
    $OXFD
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $OXFD alert in real time by email
    SC 13G/A 1 OXFD_SC13G_Feb2021.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    OXFORD IMMUNOTEC GLOBAL PLC
    (Name of Issuer)

    ORDINARY SHARES, £0.006705 NOMINAL VALUE PER SHARE
    (Title of Class of Securities)

    G6855A103
    (CUSIP Number)

    FEBRUARY 5, 2021
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    2
      of   
    15

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Core Strategies (US) LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,170,699
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,170,699
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,170,699
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     4.6%
    12 TYPE OF REPORTING PERSON

     OO


                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    3
      of   
    15

    1
     NAMES OF REPORTING PERSONS
     
     Integrated Assets, Ltd.
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,266
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,266
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,266
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.0%
    12 TYPE OF REPORTING PERSON

     
    CO


                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    4
      of   
    15

    1
     NAMES OF REPORTING PERSONS
     
     ICS Opportunities, Ltd.
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     154,419
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     154,419
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     154,419
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.6%
    12 TYPE OF REPORTING PERSON

     
    CO


                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    5
      of   
    15

    1
     NAMES OF REPORTING PERSONS
     
     Millennium International Management LP
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     155,685
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     155,685
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     155,685
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     0.6%
    12 TYPE OF REPORTING PERSON

     
    PN


                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    6
      of   
    15

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,326,384
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,326,384
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,326,384
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.2%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    7
      of   
    15

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,326,384
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,326,384
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,326,384
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.2%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    8
      of   
    15

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   þ
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     1,326,384
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     1,326,384
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     1,326,384
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.2%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    G6855A103

     SCHEDULE 13G

    Page  
    9
      of   
    15
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      Oxford Immunotec Global PLC, a public limited company incorporated under the laws of England and Wales (the "Issuer").
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    94C Innovation Drive, Milton Park
    Abingdon OX14 4RZ, United Kingdom

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Integrated Core Strategies (US) LLC
    c/o Millennium Management LLC
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Delaware
     
       
     
      Integrated Assets, Ltd.
    c/o Millennium International Management LP
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Cayman Islands
     
       
     
      ICS Opportunities, Ltd.
    c/o Millennium International Management LP
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Cayman Islands
     
       
     
      Millennium International Management LP
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Delaware
     
       
     
      Millennium Management LLC
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    666 Fifth Avenue
    New York, New York 10103
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    ordinary shares, £0.006705 nominal value per share ("Ordinary Shares")
     
      (e) CUSIP Number:
         
        G6855A103


                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    10
      of   
    15

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    G6855A103

     SCHEDULE 13G

    Page  
    11
      of   
    15
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       As of the close of business on February 10, 2021:

       i) Integrated Core Strategies (US) LLC, a Delaware limited liability company ("Integrated Core Strategies"), beneficially owned 1,170,699 of the Issuer’s Ordinary Shares;

       ii) Integrated Assets, Ltd., an exempted company organized under the laws of the Cayman Islands ("Integrated Assets"), beneficially owned 1,266 of the Issuer’s Ordinary Shares; and

       iii) ICS Opportunities, Ltd., an exempted company organized under the laws of the Cayman Islands ("ICS Opportunities"), beneficially owned 154,419 of the Issuer’s Ordinary Shares, which together with the Issuer’s Ordinary Shares beneficially owned by Integrated Core Strategies and Integrated Assets represented 1,326,384 of the Issuer’s Ordinary Shares or 5.2% of the Issuer’s Ordinary Shares outstanding.

       Millennium International Management LP, a Delaware limited partnership ("Millennium International Management"), is the investment manager to Integrated Assets and ICS Opportunities and may be deemed to have shared voting control and investment discretion over securities owned by Integrated Assets and ICS Opportunities.

       Millennium Management LLC, a Delaware limited liability company ("Millennium Management"), is the general partner of the managing member of Integrated Core Strategies and may be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Management is also the general partner of the 100% owner of Integrated Assets and ICS Opportunities and may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Assets and ICS Opportunities.

       Millennium Group Management LLC, a Delaware limited liability company ("Millennium Group Management"), is the managing member of Millennium Management and may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Group Management is also the general partner of Millennium International Management and may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Assets and ICS Opportunities.

       The managing member of Millennium Group Management is a trust of which Israel A. Englander, a United States citizen ("Mr. Englander"), currently serves as the sole voting trustee. Therefore, Mr. Englander may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies, Integrated Assets and ICS Opportunities.

       The foregoing should not be construed in and of itself as an admission by Millennium International Management, Millennium Management, Millennium Group Management or Mr. Englander as to beneficial ownership of the securities owned by Integrated Core Strategies, Integrated Assets or ICS Opportunities, as the case may be.

    (b) Percent of Class:   

       As of the close of business on February 10, 2021, Millennium Management, Millennium Group Management and Mr. Englander may be deemed to have beneficially owned 1,326,384 of the Issuer’s Ordinary Shares or 5.2% of the Issuer’s Ordinary Shares outstanding (see Item 4(a) above), which percentage was calculated based on 25,577,834 of the Issuer’s Ordinary Shares outstanding as of January 27, 2021, as reported in the Issuer’s proxy statement filed on January 29, 2021.


                         
    CUSIP No.
     
    G6855A103

     SCHEDULE 13G

    Page  
    12
      of   
    15

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       -0-

    (ii) Shared power to vote or to direct the vote

       1,326,384 (See Item 4(b))

     (iii) Sole power to dispose or to direct the disposition of

       -0-

    (iv) Shared power to dispose or to direct the disposition of

       1,326,384 (See Item 4(b))

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    13
      of   
    15

    Exhibits:

    Exhibit I: Joint Filing Agreement, dated as of February 10, 2021, by and among Integrated Core Strategies (US) LLC, Integrated Assets, Ltd., ICS Opportunities, Ltd., Millennium International Management LP, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    14
      of   
    15
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: February 10, 2021

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    INTEGRATED ASSETS, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM INTERNATIONAL MANAGEMENT LP

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    G6855A103

    SCHEDULE 13G

    Page  
    15
      of   
    15
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Ordinary Shares, £0.006705 nominal value per share, of Oxford Immunotec Global PLC, a public limited company incorporated under the laws of England and Wales, will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: February 10, 2021

    INTEGRATED CORE STRATEGIES (US) LLC

    By: Integrated Holding Group LP,
           its Managing Member

    By: Millennium Management LLC,
           its General Partner

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    INTEGRATED ASSETS, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    ICS OPPORTUNITIES, LTD.

    By: Millennium International Management LP,
           its Investment Manager

    By: /s/ Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM INTERNATIONAL MANAGEMENT LP

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $OXFD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OXFD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OXFD
    SEC Filings

    See more
    • SEC Form 15-12B filed by Oxford Immunotec Global PLC

      15-12B - Oxford Immunotec Global PLC (0001586049) (Filer)

      3/18/21 4:35:17 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 POS filed

      S-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)

      3/12/21 4:38:00 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 POS filed

      S-8 POS - Oxford Immunotec Global PLC (0001586049) (Filer)

      3/12/21 4:35:16 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

      OXFORD, United Kingdom and MARLBOROUGH, Mass., March 4, 2021 /PRNewswire/ -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to SARS-CoV-2 in human whole blood. The company has filed an EUA request to the FDA for the test. T-SPOT®.COVID, a Test from Oxford Immunotec Global PLC for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection Serology does not give the full picture of the adaptive immune response to SARS-CoV-2 infe

      3/4/21 2:26:00 PM ET
      $OXFD
      $PKI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea

      OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea. Under this agreement, GC MS will market/sell, MESDIA will import, and Oxford Immunotec Korea will provide overall support for the T-SPOT Discovery SARS-CoV-2 kit. Based on the Company’s T-SPOT technology, the only globally approved ELISPOT currently used clinically for the diagnosis of Tuberculosis infection; the T-SPOT Discovery SARS-CoV-2 kit is

      2/8/21 9:15:00 AM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses

      OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit. The kit, for research use only, has been updated using the Company’s growing expertise of the T cell response to SARS-CoV-2 infection. The previous T-SPOT Discovery SARS-CoV-2 kit configuration included five antigen wells, each containing a mix of peptides representing target epitopes derived from the virus, with areas of high homology to endemic coronaviruses removed. Using the Company’s growing results database, it has

      2/4/21 9:15:00 AM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Herm Rosenman disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

      4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

      3/12/21 4:37:45 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: E T Matthew Mclaughlin disposed to the issuer $1,350,954 worth of Ordinary Shares (61,407 units at $22.00), decreasing direct ownership by 100% to 0 units

      4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

      3/12/21 4:37:19 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: A Richard Sandberg disposed to the issuer $89,782 worth of Ordinary Shares (4,081 units at $22.00), decreasing direct ownership by 100% to 0 units

      4 - Oxford Immunotec Global PLC (0001586049) (Issuer)

      3/12/21 4:36:57 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Oxford Immunotec Global PLC

      SC 13G - Oxford Immunotec Global PLC (0001586049) (Subject)

      5/7/21 5:05:21 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Oxford Immunotec Global PLC (0001586049) (Subject)

      3/8/21 5:05:38 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Oxford Immunotec Global PLC (0001586049) (Subject)

      2/17/21 3:14:15 PM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Leadership Updates

    Live Leadership Updates

    See more
    • PerkinElmer to Acquire Oxford Immunotec Global PLC

      WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”). Under the terms of the Acquisition, Oxford Immunotec shareholders will be entitled to receive USD 22.00 in cash for each outstanding ordina

      1/7/21 7:00:00 AM ET
      $PKI
      $OXFD
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $OXFD
    Financials

    Live finance-specific insights

    See more
    • Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan

      OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of The Sysmex Corporation (Sysmex), in Japan. Under the agreement, RIKEN Genesis will exclusively distribute the T-SPOT Discovery SARS-CoV-2 kit (Research Use Only), developed by Oxford Immunotec for the detection and measurement of SARS-CoV-2 specific T cells, which may offer new insight into immunity to SARS-CoV-2 infection. Based on the company’s T-SPOT technology, the only globally approved E

      12/2/20 9:00:00 AM ET
      $OXFD
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care